表紙
市場調査レポート

Kadcyla(HER2陽性乳癌)- 予測と市場分析

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 316766
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Kadcyla(HER2陽性乳癌)- 予測と市場分析 Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
出版日: 2014年09月30日 ページ情報: 英文 54 Pages
概要

HER2陽性乳癌は、世界で2番目に多い癌で、女性に最もよく見られる癌です。Kadcyla(ado-trastuzumab)は、Rocheによる第3のHER2標的モノクローナル抗体で、2013年2月にFDAで承認され、2013年9月に日本の厚生労働省、2013年11月にEMAで承認されました。

当レポートでは、HER2陽性乳癌の治療薬であるKadcylaについて調査分析し、疾患の概要と治療ガイドライン、競合情勢、製品情報、売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 乳房の基本構造
  • 乳癌の病期分類
  • 予後
  • QOL
  • 症状

第4章 疾患の管理

  • 治療の概要

第5章 競合評価

  • 概要

第6章 Kadcyla(ado-trastuzumab emtansine、T-DM1)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC465DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Kadcyla (ado-trastuzumab) is Roche's third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).

Scope

  • Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Kadcyla including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Kadcyla for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Kadcyla performance
  • Obtain sales forecast for Kadcyla from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Basic Breast Anatomy
  • 3.3. Breast Cancer Staging
  • 3.4. Prognosis
  • 3.5. Quality of Life
  • 3.6. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 4.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
    • 4.1.3. Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5. Competitive Assessment

  • 5.1. Overview

6. Kadcyla (ado-trastuzumab emtansine, T-DM1)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed HER2-Positive Breast Cancer Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer in the US
  • Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
  • Table 4: Product Profile - Kadcyla
  • Table 5: Kadcyla SWOT Analysis, 2013
  • Table 6: Global Sales Forecast ($m) for Kadcyla, 2013-2023
  • Table 7: HER2-Positive Breast Cancer Incidence, 2013-2023
  • Table 8: Average Body Weight and Surface Area Across the 8MM
  • Table 9: Average Annual Cost of Therapy ($) - Kadcyla, Second Line
  • Table 10: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: Active Phase III Clinical Trials for Kadcyla
Back to Top